12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background. Non-alcoholic fatty liver disease (NAFLD) increases the risk of atherosclerosis but this risk may differ between metabolically- vs. genetically-driven NAFLD. High-density lipoprotein (HDL)-mediated cholesterol efflux (CEC) and plasma loading capacity (CLC) are key factors in atherogenesis. Aims. To test whether CEC and CLC differ between metabolically- vs. genetically-determined NAFLD. Methods: CEC and CLC were measured in 19 patients with metabolic NAFLD and wild-type PNPLA3 genotype (Group M), 10 patients with genetic NAFLD carrying M148M PNPLA3 genotype (Group G), and 10 controls PNPLA3 wild-types and without NAFLD. CEC and CLC were measured ex vivo by isotopic and fluorimetric techniques using cellular models. Results: Compared with Group G, Group M showed reduced total CEC (−18.6%; p < 0.001) as well as that mediated by cholesterol transporters (−25.3% ABCA1; −16.3% ABCG1; −14.8% aqueous diffusion; all p < 0.04). No difference in CEC was found between Group G and controls. The presence of metabolic syndrome further impaired ABCG1-mediated CEC in Group M. Group M had higher plasma-induced CLC than Group G and controls ( p < 0.001). Conclusions: Metabolically-, but not genetically-, driven NAFLD associates with dysfunctional HDL-meditated CEC and abnormal CLC. These data suggest that the mechanisms of anti-atherogenic protection in metabolic NAFLD are impaired.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

          Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

              Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease "MAFLD" was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.
                Bookmark

                Author and article information

                Journal
                Biomedicines
                Biomedicines
                biomedicines
                Biomedicines
                MDPI
                2227-9059
                18 December 2020
                December 2020
                : 8
                : 12
                : 625
                Affiliations
                [1 ]Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy; laura.derasmo@ 123456uniroma1.it (L.D.); marcello.arca@ 123456uniroma1.it (M.A.)
                [2 ]Department of Food and Drug, University of Parma, 43124 Parma, Italy; annalisa.ronca@ 123456studenti.unipr.it (A.R.); elda.favari@ 123456unipr.it (E.F.)
                [3 ]Department of Chemistry, Life Science, and Environmental Sustainability, University of Parma, 43124 Parma, Italy; matteo.manfredini@ 123456unipr.it
                [4 ]Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy; francesco.baratta@ 123456uniroma1.it (F.B.); daniele.pastori@ 123456uniroma1.it (D.P.); maria.delben@ 123456uniroma1.it (M.D.B.)
                [5 ]Department of Diagnostic of Radiological, Oncological and Anatomopathological Sciences, Sapienza University of Rome, 00161 Rome, Italy; micdimartino@ 123456hotmail.it
                [6 ]Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy; fabrizio.ceci@ 123456uniroma1.it
                [7 ]Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00161 Rome, Italy; francesco.angelico@ 123456uniroma1.it
                [8 ]Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy; chiara.pavanello@ 123456unimi.it (C.P.); marta.turri@ 123456unimi.it (M.T.); laura.calabresi@ 123456unimi.it (L.C.)
                Author notes
                [* ]Correspondence: alessia.dicostanzo@ 123456uniroma1.it ; Tel.: +39-06-445-1354; Fax: +39-06-446-3534
                [†]

                These authors equally contributed to the work.

                Author information
                https://orcid.org/0000-0002-9911-693X
                https://orcid.org/0000-0001-7377-5921
                https://orcid.org/0000-0003-1708-272X
                https://orcid.org/0000-0001-6357-5213
                https://orcid.org/0000-0003-4051-4922
                https://orcid.org/0000-0002-9372-3923
                https://orcid.org/0000-0003-1199-8454
                https://orcid.org/0000-0001-5892-9857
                https://orcid.org/0000-0003-3786-0883
                Article
                biomedicines-08-00625
                10.3390/biomedicines8120625
                7766839
                33352841
                bb1425fb-ebe7-46c1-b479-042443363222
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 30 November 2020
                : 15 December 2020
                Categories
                Article

                metabolic nafld,genetic nafld,reverse cholesterol transport (rct),cholesterol efflux capacity (cec),cholesterol loading capacity (clc)

                Comments

                Comment on this article